<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C1112570" disease_type="Neoplastic Process" abbrv="">Paraneoplastic pemphigus</z:e> (PNP) is a life-threatening, autoimmune, <z:mp ids='MP_0001208'>blistering</z:mp>-<z:e sem="disease" ids="C0037274" disease_type="Disease or Syndrome" abbrv="">skin disease</z:e>, associated with various <z:hpo ids='HP_0002664'>neoplasms</z:hpo>, particularly <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>It is characterized by polymorphic cutaneous manifestations, severe mucosal <z:mpath ids='MPATH_580'>erosions</z:mpath> and internal organ involvement, and marked by unique histopathological features and a complex autoantigenic profile </plain></SENT>
<SENT sid="2" pm="."><plain>To define this condition, the encompassing term 'paraneoplastic autoimmune multiorgan syndrome' has also been suggested </plain></SENT>
<SENT sid="3" pm="."><plain>Although a number of immunosuppressive treatments have been used in PNP, its mortality rate remains high </plain></SENT>
<SENT sid="4" pm="."><plain>The anti-CD20 monoclonal antibody, rituximab, was successfully administered to two patients with PNP and CD20(+) follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> in 2001 </plain></SENT>
<SENT sid="5" pm="."><plain>Since then, good responses to rituximab by different refractory <z:hpo ids='HP_0002960'>autoimmune disorders</z:hpo> have been reported, but further controlled trials are warranted to evaluate the effectiveness and safety of this agent as a second-line treatment for PNP </plain></SENT>
</text></document>